ZLAB vs DNLI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZLAB · Zai Lab$25.48 ▲ 12.74%
DNLI · Denali Therapeutics$20.07 ▲ 1.77%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZLAB +16.4%
- DNLI +28.7%
Head to head
| Metric | ZLAB | DNLI |
|---|---|---|
| Price | $25.48 | $20.07 |
| Change today | ▲ 12.74% | ▲ 1.77% |
| Market cap | $2.87B | $3.22B |
| Return, 3 months | +8.1% | -19.7% |
| Return, year to date | +44.4% | +21.6% |
| Return, 1 year | +16.3% | +33.6% |
| P/E (TTM) | – | – |
| P/B | 5.1 | 3.5 |
| P/E percentile vs own 5y | 18th | 73rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -3.3% | – |
| Net profit growth (YoY) | -24.8% | -2.8% |
| Gross margin | 56.5% | 97.4% |
| Operating margin | -57.4% | -15,058.2% |
| Net margin | -41.9% | -14,191.2% |
| Return on equity | -26.9% | -54.9% |
| Analyst target vs. price | +54.4% | +79.9% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 58 | 54 |
| 30-day volatility | 68.7% | 46.7% |
| Max drawdown, 1 year | -39.1% | -35.3% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DNLI is the largest of the group by market value.
- DNLI has returned the most over the past year.
- ZLAB keeps the most profit per dollar of sales.
- DNLI has been the calmest stock over the last 30 days.